soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Presented at ACC.25: Among participants soul trial oral semaglutide cardiovascular

Name: soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Presented at ACC.25: Among participants soul trial oral semaglutide cardiovascular
Brand: skorenge.com
SKU: 55195753580
Price: 21.79 USD
Availability: InStock
Rating: 4.036 (5 reviews)

SKU: 55195753580

4.0

SEK21.79 SEK64.79

Pay in 4 interest-free payments of $5.45 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results SOUL: Oral Semaglutide Bests Usual Care in High Risk Type 2 Diabetes Oral Semaglutide Lowers Cardiovascular Events by 14% in Type 2 Diabetes Patients with Heart, Kidney Disease Applied Clinical Trials Online Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all cause mortality vs sitagliptin, but tirzepatide offered no Results of SOUL Trial with Oral Semaglutide

Store: skorenge.com · Domain: skorenge.com

Description

Database searches and study identification We performed comprehensive database searches in PubMed, Embase, ClinicalKey, Cochrane CENTRAL, ProQuest, ScienceDirect, Web of Science, and ClinicalTrials.gov (Additional file: Tab

doi: 10.1016/j.lwt.2013.05.006